April 20, 2024
Lupus Therapeutic Market

The Global Lupus Therapeutic Market Is Estimated To Witness High Growth Owing To Rising Prevalence Of Lupus Disease

The global Lupus therapeutic market has been witnessing steady growth owing to rising prevalence of lupus disease across the globe. Lupus is an autoimmune disease that occurs when body’s immune system mistakenly attacks its own healthy tissues and organs. The disease can affect various parts of the body like joints, heart, lungs, kidneys and brain. Lupus therapeutic drugs aim to control disease symptoms, prevent damage to vital organs and reduce risk of complications.Key drugs available are glucocorticoids, immunosuppressants, antiproliferatives, NSAIDs, antimalarials and biologics.

The Global Lupus therapeutic Market is estimated to be valued at US$ 3497 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Lupus Therapeutic Market Size are Pfizer Inc., Abbott Laboratories, AstraZeneca Plc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Sanofi S.A. Key players are focusing on drug development and licensing & acquisition activities to strengthen their product pipelines and market position. Growing awareness about lupus and available therapies is creating new opportunities for market players.

Rising incidence of lupus globally due to environmental factors is driving demand for lupus therapeutics. International expansion by major players into developing regions of Asia Pacific and Latin America owing to large patient pools will aid market growth over forecast period.

Market Drivers

Increasing prevalence of lupus disease owing to genetic and environmental risk factors is a major driver for this market. According to estimates, about 5 million people worldwide suffer from lupus. Growing awareness about early diagnosis and availability of treatment options is encouraging patients to seek medical help. Favorable government policies supporting drug development for rare and autoimmune diseases is fostering innovation. Unmet needs in managing flares and reducing harmful side effects of steroids and immunosuppressants will spur R&D efforts by pharmaceutical companies.

PEST Analysis
Political: The political factors affecting this Lupus Therapeutic Market include increasing government funding for rare disease research and new healthcare reforms aiming to improve access to treatments.

Economic: Factors such as rising healthcare expenditure and growing per capita disposable incomes are driving demand in developing markets. However, high treatment costs pose challenges.

Social: Increased awareness through patient advocacy groups is reducing stigma around autoimmune diseases. Social media is empowering communities to share experiences and information.

Technological: Advancements in biomarkers and diagnostics are improving early detection and disease monitoring. Targeted drug delivery systems and combination therapies are optimizing treatment protocols. Use of real-world data and digital tools in clinical trials is accelerating research.

North America currently dominates the market in terms of value, accounting for over 40% share. Key contributors include the United States, followed by Canada. High adoption of promising therapies, presence of prominent pharmaceutical companies, and strong reimbursement framework aid market growth in the region.

The Asia Pacific region is poised to be the fastest growing market over the forecast period, expanding at around 8%. Rapidly developing healthcare infrastructure, growing medical tourism, rising incidence rates, and increasing generic drug approvals are driving the market in countries such as China, India and South Korea.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.